Branham Law Group Investigates Pfizer for Qualitest Packaging Error Recall

DALLAS--(BUSINESS WIRE)-- Branham Law Group, LLP, a Dallas, Texas law firm, is investigating Pfizer (NYSE: PFE) for its recall of 14 lots of Lo/Ovral-28 tablet packs and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Pfizer manufactured both drugs and they were marketed in the United States by Akrimax Rx Products under the Akrimax Pharmaceuticals brand. The expiration dates on these contraceptives range from July 31, 2013 through March 31, 2014.

“We are very concerned about these recalls and the potential effects of Pfizer’s error,” said Trey Branham, Managing Partner of the Branham Law Group. If you currently take Lo/Ovral-28 tablet packs, Norgestrel or Ethinyl Estradiol, and have suffered health complications or pregnancy as a result of the mis-packaged medication or have a question about the recall and your rights, please contact Branham Law Group, LLP immediately. Branham Law Group has extensive experience in pharmaceutical litigation. Anyone taking these drugs - or anyone with knowledge about this recall - should contact lawyer Trey Branham at [email protected] or 1-855-722-5910.

The Branham Law Group, LLP has extensive experience in pharmaceutical litigation and catastrophic injury. The Branham Law Group also advises whistleblowers on appropriate courses of actions.



CONTACT:

Branham Law Group, LLP
Charles W. “Trey” Branham, III, 855-722-5910
www.branhamlawgroup.com

KEYWORDS:   United States  North America  Texas

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Professional Services  Legal

MEDIA:

Logo
 Logo

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.